share_log

Critical Survey: Better Therapeutics (BTTX) Versus Its Rivals

Critical Survey: Better Therapeutics (BTTX) Versus Its Rivals

批判性调查：与竞争对手相比，更好的治疗方法（BTTX）
Defense World ·  2022/12/18 01:41

Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 publicly-traded companies in the "Health services" industry, but how does it compare to its rivals? We will compare Better Therapeutics to related businesses based on the strength of its valuation, institutional ownership, profitability, risk, dividends, analyst recommendations and earnings.

Better Treateutics(纳斯达克代码：BTTX-GET Rating)是“健康服务”行业的33家上市公司之一，但与其竞争对手相比如何？我们将根据其估值、机构所有权、盈利能力、风险、股息、分析师建议和收益的实力，将Better Treateutics与相关业务进行比较。

Institutional and Insider Ownership

机构和内部人持股

7.5% of Better Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 21.6% of shares of all "Health services" companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Better Treateutics 7.5%的股份由机构投资者持有。相比之下，所有“健康服务”公司48.6%的股份由机构投资者持有。Better Treateutics 59.4%的股份由公司内部人士持有。相比之下，所有“健康服务”公司21.6%的股份由公司内部人士持有。强大的机构持股表明，捐赠基金、对冲基金和大型基金管理公司相信，一家公司的长期表现将好于大盘。

Get
到达
Better Therapeutics
更好的治疗学
alerts:
警报：

Valuation and Earnings

估值和收益

This table compares Better Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.

此表比较了Better Treateutics及其竞争对手的营收、每股收益(EPS)和估值。

Gross Revenue Net Income Price/Earnings Ratio
Better Therapeutics $10,000.00 -$40.33 million -0.74
Better Therapeutics Competitors $1.36 billion -$98.47 million 36.86
总收入 净收入 市盈率
更好的治疗学 $10,000.00 -4,033万元 -0.74
Better Treateutics的竞争对手 13.6亿美元 -9,847万元 36.86
Better Therapeutics' rivals have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Better Treateutics的竞争对手比Better Treeutics的收入更高，但收益更低。Better Treateutics的市盈率低于竞争对手，这表明它目前比行业内的其他公司更负担得起。

Analyst Ratings

分析师评级

This is a summary of recent ratings and target prices for Better Therapeutics and its rivals, as provided by MarketBeat.

这是由MarketBeat提供的Better Treateutics及其竞争对手最近的评级和目标价格摘要。

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Better Therapeutics 0 0 2 0 3.00
Better Therapeutics Competitors 7 131 277 0 2.65
销售评级 保持评级 购买评级 强劲的买入评级 评级分数
更好的治疗学 0 0 2 0 3.00
Better Treateutics的竞争对手 7 131 277 0 2.65

Better Therapeutics presently has a consensus target price of $14.00, suggesting a potential upside of 839.60%. As a group, "Health services" companies have a potential upside of 89.14%. Given Better Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Better Therapeutics is more favorable than its rivals.

Better Treateutics目前的共识目标价为14.00美元，这意味着潜在的上涨839.60%。作为一个整体，“健康服务”公司有89.14%的潜在上行空间。鉴于Better Treeutics更高的共识评级和更高的可能上行空间，研究分析师显然认为Better Treateutics比其竞争对手更有利。

Volatility & Risk

波动性与风险

Better Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' rivals have a beta of 1.19, indicating that their average share price is 19% more volatile than the S&P 500.

Better Treateutics的贝塔系数为1.36，这表明其股价的波动性比标准普尔500指数高36%。相比之下，Better Treateutics的竞争对手的贝塔系数为1.19，这表明它们的平均股价波动性比标准普尔500指数高19%。

Profitability

盈利能力

This table compares Better Therapeutics and its rivals' net margins, return on equity and return on assets.

下表比较了Better Treeutics及其竞争对手的净利润率、股本回报率和资产回报率。

Net Margins Return on Equity Return on Assets
Better Therapeutics N/A -200.73% -114.68%
Better Therapeutics Competitors -325.87% -676.77% -37.31%
净利润率 股本回报率 资产回报率
更好的治疗学 不适用 -200.73% -114.68%
Better Treateutics的竞争对手 -325.87% -676.77% -37.31%

Summary

摘要

Better Therapeutics beats its rivals on 8 of the 12 factors compared.

Better Treateutics在比较的12个因素中有8个击败了竞争对手。

About Better Therapeutics

关于Better Treatetics

(Get Rating)

(获取评级)

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.

Better Treateutics，Inc.，一家处方数字治疗公司，开发了一种认知行为疗法，以解决心脏代谢性疾病的原因。该公司开发基于软件的处方数字疗法平台，用于治疗糖尿病、心脏病和其他心脏代谢疾病。其临床开发候选药物旨在治疗心脏代谢性疾病，包括2型糖尿病、高血压、高脂血症、非酒精性脂肪性肝病、非酒精性脂肪性肝炎和慢性肾脏疾病。该公司的主要候选产品是BT-001，这是一种治疗2型糖尿病的研究PDT平台。Better Treateutics，Inc.成立于2015年，总部位于加利福尼亚州旧金山。

Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

每天收到更好的治疗新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯，接收最新新闻和分析师对Better Treateutics和相关公司的评级的每日摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发